Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerStructure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold MorphingFractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study GroupTherapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsClinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancerPhase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapyDesign, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.Perspectives on biologically active camptothecin derivatives.Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated proteinStrategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancerSensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinomaIrinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivativesPhase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus genome.New strategy for overcoming resistance to chemotherapy of ovarian cancer.Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy.Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.Formulation and evaluation of irinotecan suppository for rectal administration.A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update.Current perspectives on camptothecins in cancer treatmentCPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
P2860
Q26775949-FED63EE5-4FAD-4DAF-A7B2-E52F43A56971Q27675773-F47E3527-79D1-412E-B0C4-2F65F23EDC8EQ28343462-F92DC82A-3D94-48C5-9EB9-8A277A562FE4Q28379054-7068A0B7-9B71-4441-8778-6E11C4A99DECQ33429673-40423D1E-FDE7-4547-A034-AFE2B04E7B61Q33746897-8889D342-8012-4987-A140-BA81765DA4D3Q33951823-BADED9E1-8020-4068-8586-FA4F4E019E3BQ34468628-A0E295E6-CFD6-4E5B-ACC1-EBAE07AB8F02Q35977364-E6A246AE-1A42-4782-AAAB-8D6130CC9152Q36079661-2DA151BB-A0DF-43B8-B2B2-C89C747BB852Q36114656-928119D1-7E42-4B5A-A1FD-CE087CEBDF4FQ36295072-2F005320-5630-4DEE-8FE1-06F4FB14F328Q36372894-82882DC3-0221-4BC2-BEA8-0CF5753B3CD7Q36512681-CC4C5E16-5204-4C7D-9903-ABED7C604187Q36617921-3C1406EF-1FFC-42E6-9FAE-93A173BC04ECQ36641182-25C86D09-E893-42B9-B60A-64441604DB38Q36641418-4D2E0072-7484-4636-B196-ED2269F638F9Q36646313-168F860C-D49C-4316-9F6E-325576FBE511Q36695419-E24D1EF9-DD23-4599-AA49-16A38436D3E2Q36805608-364274A2-8577-4075-A552-138E7C9FD96FQ37091425-5F65F7FA-3940-4985-A960-3B1AB483C346Q37123264-FFE88A76-7D3A-43A5-B348-0C7B99747959Q37165926-13C6D0A5-4051-4050-9406-355D75E0A1EFQ37341645-52B0A1E1-F6B2-4FD8-94D5-E960CEEE91A9Q37378223-423C294F-2610-480C-96CB-ECC24CA8838AQ37381210-FE25EFF3-CBA6-4A6A-BF36-0F6B04A1DE88Q37459147-3EB68CEC-9175-46BE-91DE-04A9F17545A8Q37662264-418B6429-A0A4-4DE8-96DF-E7CDBCE3C494Q38166233-57D24D9C-3560-456C-871B-CC065C1C2622Q40876335-0269135E-EC41-4A14-8FB1-E51A7FED3B1BQ41064010-1AFFC5E2-EAAB-4DBB-ABCA-2EC05220490DQ41444709-9CC181BF-8E39-4E76-9F78-006FAE98EE76Q41779092-5F673167-CE5A-4D0C-985D-8B2E9531B1E7Q41866854-4BD3673C-AE21-496C-B245-071569E1D002Q42690847-B699E9A3-FEBA-4525-A88D-3D3368643E39Q42691338-A318B984-5474-4148-8CD8-CF2F991805D3Q42715927-E746D04D-1B70-4C70-8BEA-585EDB295159Q43827787-D06867D4-5ADE-4392-A34E-F1ABC7E201D6Q49164024-D014134D-8958-45ED-A397-5B9D3D19095CQ49164031-54FD4C5D-16CC-4E4E-AFEF-D400A154B3AE
P2860
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@en
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@nl
type
label
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@en
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@nl
prefLabel
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@en
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@nl
P2093
P1433
P1476
Antitumor activity of 7-ethyl- ...... thecin, against murine tumors.
@en
P2093
M Takeuchi
T Kunimoto
T Miyasaka
T Yokokura
P304
P407
P577
1987-11-01T00:00:00Z